tps://www.stuvia.com/user/filwe1099salmin1
https://www.stuvia.com/user/filwe1099salmin1
https://www.stuvia.com/user/filwe1099salminNAMS
of 26https://www.stuvia.com/user/filwe1099salmin
of 26https://www.stuvia.com/user/filwe1099salmin
Certification Exam Qs & Ashttps://www.stuvi
NAMS Certification
Physiology of VMS
-thermoregulatory center altered by increase in KNDy neurons
-activation of NK3R causes hot flashes
-blockade of NK3R reduces/eliminates hot flashes
-may also be affected by: serotonin, epinephrine, and norepinephrine;
parasympathetic nerve activity
Off label rx for VMS
-SSRIs
-SNRIs
-Gabapentinoids
-Clonidine
-Oxybutynin
pg. 1
tps://www.stuvia.com/user/filwe1099salmin1
https://www.stuvia.com/user/filwe1099salmin1
https://www.stuvia.com/user/filwe1099salmin1
of 26https://www.stuvia.com/user/filwe1099salmin
of 26https://www.stuvia.com/user/filwe1099salmin
of 26https://www.stuvia.com/user/filwe1099salm
,tps://www.stuvia.com/user/filwe1099salmin2
https://www.stuvia.com/user/filwe1099salmin2
https://www.stuvia.com/user/filwe1099salminNAMS
of 26https://www.stuvia.com/user/filwe1099salmin
of 26https://www.stuvia.com/user/filwe1099salmin
Certification Exam Qs & Ashttps://www.stuvi
Studies on Fractional Co2 Laser for GSM
-not FDA approved
-vaginal symptoms and sexual function scores increased significantly at 3
mon; noted continued improvement at 1y
Ospemifene (Osphena) indications and MOA
-for treatment of dyspareunia
-decreases vaginal pH
-improves vaginal dryness
-shifts vaginal maturational index to superficial cells
-estrogen agonist/antagonist
Ospemifene (Osphena) adverse effects
pg. 2
tps://www.stuvia.com/user/filwe1099salmin2
https://www.stuvia.com/user/filwe1099salmin2
https://www.stuvia.com/user/filwe1099salmin2
of 26https://www.stuvia.com/user/filwe1099salmin
of 26https://www.stuvia.com/user/filwe1099salmin
of 26https://www.stuvia.com/user/filwe1099salm
,tps://www.stuvia.com/user/filwe1099salmin3
https://www.stuvia.com/user/filwe1099salmin3
https://www.stuvia.com/user/filwe1099salminNAMS
of 26https://www.stuvia.com/user/filwe1099salmin
of 26https://www.stuvia.com/user/filwe1099salmin
Certification Exam Qs & Ashttps://www.stuvi
-increase in uterine polyps
-proliferative endometrium
-slight increased risk of hemorrhagic stroke and VTE
-can increase VMS
treatment of urge incontinence
-behavioral modifications
-overactivity of the detrusor muscle
-antimuscarinics: oxybutynin
-nerve stimulation
-botox
pelvic floor muscles - superficial
-transverse perineal
-bulbospongiosus,
pg. 3
tps://www.stuvia.com/user/filwe1099salmin3
https://www.stuvia.com/user/filwe1099salmin3
https://www.stuvia.com/user/filwe1099salmin3
of 26https://www.stuvia.com/user/filwe1099salmin
of 26https://www.stuvia.com/user/filwe1099salmin
of 26https://www.stuvia.com/user/filwe1099salm
https://www.stuvia.com/user/filwe1099salmin1
https://www.stuvia.com/user/filwe1099salminNAMS
of 26https://www.stuvia.com/user/filwe1099salmin
of 26https://www.stuvia.com/user/filwe1099salmin
Certification Exam Qs & Ashttps://www.stuvi
NAMS Certification
Physiology of VMS
-thermoregulatory center altered by increase in KNDy neurons
-activation of NK3R causes hot flashes
-blockade of NK3R reduces/eliminates hot flashes
-may also be affected by: serotonin, epinephrine, and norepinephrine;
parasympathetic nerve activity
Off label rx for VMS
-SSRIs
-SNRIs
-Gabapentinoids
-Clonidine
-Oxybutynin
pg. 1
tps://www.stuvia.com/user/filwe1099salmin1
https://www.stuvia.com/user/filwe1099salmin1
https://www.stuvia.com/user/filwe1099salmin1
of 26https://www.stuvia.com/user/filwe1099salmin
of 26https://www.stuvia.com/user/filwe1099salmin
of 26https://www.stuvia.com/user/filwe1099salm
,tps://www.stuvia.com/user/filwe1099salmin2
https://www.stuvia.com/user/filwe1099salmin2
https://www.stuvia.com/user/filwe1099salminNAMS
of 26https://www.stuvia.com/user/filwe1099salmin
of 26https://www.stuvia.com/user/filwe1099salmin
Certification Exam Qs & Ashttps://www.stuvi
Studies on Fractional Co2 Laser for GSM
-not FDA approved
-vaginal symptoms and sexual function scores increased significantly at 3
mon; noted continued improvement at 1y
Ospemifene (Osphena) indications and MOA
-for treatment of dyspareunia
-decreases vaginal pH
-improves vaginal dryness
-shifts vaginal maturational index to superficial cells
-estrogen agonist/antagonist
Ospemifene (Osphena) adverse effects
pg. 2
tps://www.stuvia.com/user/filwe1099salmin2
https://www.stuvia.com/user/filwe1099salmin2
https://www.stuvia.com/user/filwe1099salmin2
of 26https://www.stuvia.com/user/filwe1099salmin
of 26https://www.stuvia.com/user/filwe1099salmin
of 26https://www.stuvia.com/user/filwe1099salm
,tps://www.stuvia.com/user/filwe1099salmin3
https://www.stuvia.com/user/filwe1099salmin3
https://www.stuvia.com/user/filwe1099salminNAMS
of 26https://www.stuvia.com/user/filwe1099salmin
of 26https://www.stuvia.com/user/filwe1099salmin
Certification Exam Qs & Ashttps://www.stuvi
-increase in uterine polyps
-proliferative endometrium
-slight increased risk of hemorrhagic stroke and VTE
-can increase VMS
treatment of urge incontinence
-behavioral modifications
-overactivity of the detrusor muscle
-antimuscarinics: oxybutynin
-nerve stimulation
-botox
pelvic floor muscles - superficial
-transverse perineal
-bulbospongiosus,
pg. 3
tps://www.stuvia.com/user/filwe1099salmin3
https://www.stuvia.com/user/filwe1099salmin3
https://www.stuvia.com/user/filwe1099salmin3
of 26https://www.stuvia.com/user/filwe1099salmin
of 26https://www.stuvia.com/user/filwe1099salmin
of 26https://www.stuvia.com/user/filwe1099salm
